F. Hoffmann-La Roche Ltd: Roche to present data at ASH 2022 showcasing strength of haematology portfolio and expanding into new areas to address more patient needs

Interim data from phase III HAVEN 7 study reinforce Hemlibra's efficacy and safety in infants with severe haemophilia A without factor VIII inhibitors1New and updated data support use of Polivy in diffuse

Related Keywords

China ,Japan ,United States ,Switzerland ,America ,American ,Polatuzumab Vedotin ,Levi Garraway ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Bispecific Cevostamab ,Sileia Urech ,Venclexta Venclyxto ,Birgit Masjost ,Loren Kalm ,Karsten Kleine ,Nathalie Altermatt ,Genentech ,European Commission ,Drug Administration ,Head Of Global Product Development ,American Society Of Hematology ,Roche Group ,European Medicines Agency ,American Society ,Annual Meeting ,Chief Medical Officer ,Global Product ,Spark Therapeutics ,Tocilizumab Prior ,Refractory Multiple Myeloma ,Marked Reduction ,Cytokine Release Syndrome Incidence ,Responses After One Year ,Fixed Duration Cevostamab Therapy ,Early Experience ,First Phase ,Complement Inhibitor Naive Patients ,Paroxysmal Nocturnal Hemoglobinuria ,Exposure Response Relationship ,Heavily Pre Treated Relapsed ,Refractory Mantle Cell ,Largeb Cell Lymphoma Who Are ,Complete Remission ,Fixed Course Glofitamab ,High Response Rates ,Favorable Safety Profile ,Severe Hemophilia ,Interim Analysis ,World Safety ,European Haemophilia Safety Surveillance ,Bleeding Behavior ,Mild Hemophilia ,Longitudinal Study ,Picnichealth Hemophilia ,Case Series ,Healthcare Utilization ,Moderate Hemophilia ,Manageable Safety Profile ,Refractory Follicular Lymphoma ,Updated Results ,Pivotal Phase ,Demonstrate Promising Efficacy ,Durable Complete Responses ,Unfit Patients ,Previously Untreated Diffuse Largeb Cell ,Patients Aged About Roche ,Spark Therapeutic ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Related Quality ,Diffuse Largeb Cell Lymphoma ,Refractory Follicular Lymphoma Who Received ,Previously Untreated Diffuse Large ,Patients Aged Roche Group Media ,Hoffmann ,Oche ,Present ,Data ,022 ,Howcasing ,Strength ,Haematology ,Portfolio ,Xpanding ,Areas ,Address ,More ,Patient ,Needs ,